Literature DB >> 17535157

Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants.

Ying Wang1, Tip W Loo, M Claire Bartlett, David M Clarke.   

Abstract

The most common cause of CF (cystic fibrosis) is the deletion of Phe(508) (DeltaF508) in the CFTR [CF TM (transmembrane) conductance regulator] chloride channel. One major problem with DeltaF508 CFTR is that the protein is defective in folding so that little mature protein is delivered to the cell surface. Expression of DeltaF508 CFTR in the presence of small molecules known as correctors or pharmacological chaperones can increase the level of mature protein. Unfortunately, the efficiency of corrector-induced maturation of DeltaF508 CFTR is probably too low to have therapeutic value and approaches are needed to increase maturation efficiency. We postulated that expression of DeltaF508 CFTR in the presence of multiple correctors that bound to different sites may have an additive effect on maturation. In support of this mechanism, we found that expression of P-glycoprotein (CFTR's sister protein) processing mutants in the presence of two compounds that bind to different sites (rhodamine B and Hoechst 33342) had an additive effect on maturation. Therefore we tested whether expression of DeltaF508 CFTR in the presence of combinations of three different classes of corrector molecules would increase its maturation efficiency. It was found that the combination of the quinazoline VRT-325 together with the thiazole corr-2b or bisaminomethylbithiazole corr-4a doubled the steady-state maturation efficiency of DeltaF508 CFTR (approx. 40% of total CFTR was mature protein) compared with expression in the presence of a single compound. The additive effect of the correctors on DeltaF508 CFTR maturation suggests that they directly interact at different sites of the protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17535157      PMCID: PMC1948964          DOI: 10.1042/BJ20070478

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

Review 1.  Cystic fibrosis transmembrane conductance regulator. Structure and function of an epithelial chloride channel.

Authors:  M H Akabas
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

2.  Communication between multiple drug binding sites on P-glycoprotein.

Authors:  C Martin; G Berridge; C F Higgins; P Mistry; P Charlton; R Callaghan
Journal:  Mol Pharmacol       Date:  2000-09       Impact factor: 4.436

3.  Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.

Authors:  Ying Wang; M Claire Bartlett; Tip W Loo; David M Clarke
Journal:  Mol Pharmacol       Date:  2006-04-19       Impact factor: 4.436

4.  SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis.

Authors:  Barbara R Grubb; Sherif E Gabriel; April Mengos; Martina Gentzsch; Scott H Randell; Anna M Van Heeckeren; Michael R Knowles; Mitchell L Drumm; John R Riordan; Richard C Boucher
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11-11       Impact factor: 6.914

5.  Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR.

Authors:  R C Rubenstein; P L Zeitlin
Journal:  Am J Physiol Cell Physiol       Date:  2000-02       Impact factor: 4.249

6.  Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.

Authors:  Ying Wang; Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  Mol Pharmacol       Date:  2006-11-28       Impact factor: 4.436

7.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.

Authors:  Fredrick Van Goor; Kimberly S Straley; Dong Cao; Jesús González; Sabine Hadida; Anna Hazlewood; John Joubran; Tom Knapp; Lewis R Makings; Mark Miller; Timothy Neuberger; Eric Olson; Victor Panchenko; James Rader; Ashvani Singh; Jeffrey H Stack; Roger Tung; Peter D J Grootenhuis; Paul Negulescu
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-01-27       Impact factor: 5.464

8.  Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: evidence for simultaneous binding of both drugs.

Authors:  Miguel R Lugo; Frances J Sharom
Journal:  Biochemistry       Date:  2005-10-25       Impact factor: 3.162

9.  Transmembrane segment 1 of human P-glycoprotein contributes to the drug-binding pocket.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  Biochem J       Date:  2006-06-15       Impact factor: 3.857

Review 10.  Rescue of folding defects in ABC transporters using pharmacological chaperones.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  J Bioenerg Biomembr       Date:  2005-12       Impact factor: 3.853

View more
  30 in total

1.  Unfolding the Therapeutic Potential of Chemical Chaperones for Age-related Macular Degeneration.

Authors:  Theodor Sauer; Mrinali Patel; Chi-Chao Chan; Jingsheng Tuo
Journal:  Expert Rev Ophthalmol       Date:  2008-02

2.  Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures.

Authors:  Deborah M Cholon; Wanda K O'Neal; Scott H Randell; John R Riordan; Martina Gentzsch
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-11       Impact factor: 5.464

3.  Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism.

Authors:  C Norez; C Vandebrouck; J Bertrand; S Noel; E Durieu; N Oumata; H Galons; F Antigny; A Chatelier; P Bois; L Meijer; F Becq
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

4.  Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform.

Authors:  John P Holleran; Matthew L Glover; Kathryn W Peters; Carol A Bertrand; Simon C Watkins; Jonathan W Jarvik; Raymond A Frizzell
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 5.  Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions.

Authors:  Leah N Makley; Jason E Gestwicki
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

6.  Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele.

Authors:  Sonia Fargue; Jackie Lewin; Gill Rumsby; Christopher J Danpure
Journal:  J Biol Chem       Date:  2012-12-10       Impact factor: 5.157

7.  Clinical and molecular characterization of S1118F-CFTR.

Authors:  Himabindu Penmatsa; Carla A Frederick; Sunitha Nekkalapu; Veronica G Conoley; Weiqiang Zhang; Chunying Li; John Kappes; Dennis C Stokes; Anjaparavanda P Naren
Journal:  Pediatr Pulmonol       Date:  2009-10

8.  Syntaxin 6 and CAL mediate the degradation of the cystic fibrosis transmembrane conductance regulator.

Authors:  Jie Cheng; Valeriu Cebotaru; Liudmila Cebotaru; William B Guggino
Journal:  Mol Biol Cell       Date:  2010-02-03       Impact factor: 4.138

9.  Processing mutations disrupt interactions between the nucleotide binding and transmembrane domains of P-glycoprotein and the cystic fibrosis transmembrane conductance regulator (CFTR).

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  J Biol Chem       Date:  2008-08-16       Impact factor: 5.157

10.  Interplay between ER exit code and domain conformation in CFTR misprocessing and rescue.

Authors:  Gargi Roy; Elaine M Chalfin; Anita Saxena; Xiaodong Wang
Journal:  Mol Biol Cell       Date:  2009-12-23       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.